Depressive Symptoms and 24-Hour Urinary Norepinephrine Excretion Levels in Patients With Coronary Disease: Findings From the Heart and Soul Study
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Depressive symptoms are associated with an increased risk of cardiac events in patients with heart disease. Elevated catecholamine levels may contribute to this association, but whether depressive symptoms are associated with catecholamine levels in patients with heart disease is unknown. METHOD: The authors examined the association between depressive symptoms (defined by a Patient Health Questionnaire score > or =10) and 24-hour urinary norepinephrine, epinephrine, and dopamine excretion levels in 598 subjects with coronary disease. RESULTS: A total of 106 participants (18%) had depressive symptoms. Participants with depressive symptoms had greater mean norepinephrine excretion levels than those without depressive symptoms (65 microg/day versus 59 mug/day, with adjustment for age, sex, body mass index, smoking, urinary creatinine levels, comorbid illnesses, medication use, and cardiac function). In logistic regression analyses, participants with depressive symptoms were more likely than those without depressive symptoms to have norepinephrine excretion levels in the highest quartile and above the normal range. Depressive symptoms were not associated with dopamine or epinephrine excretion levels. CONCLUSIONS: In patients with coronary disease, depressive symptoms are associated with elevated norepinephrine excretion levels. Future longitudinal studies are needed to determine whether elevations in norepinephrine contribute to adverse cardiac outcomes in patients with depressive symptoms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The PHQ-9: Validity of a brief depression severity measure
Kroenke, K., Spitzer, R. L., & Williams, J. B. W. (2001) · Journal of General Internal Medicine · doi:10.1046/j.1525-1497.2001.016009606.x · Cited by 44,910
Spitzer, R. L. (1999) · JAMA · doi:10.1001/jama.282.18.1737 · Cited by 9,802
Plasma Norepinephrine as a Guide to Prognosis in Patients with Chronic Congestive Heart Failure
Cohn, J. N., Levine, T. B., Olivari, M. T., Garberg, V., Lura, D., Francis, G. S., Simon, A. B., & Rector, T. (1984) · New England Journal of Medicine · doi:10.1056/nejm198409273111303 · Cited by 3,125
Gold, P. W., & Chrousos, G. P. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001032 · Cited by 1,274
Holsboer, F. (1999) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(98)90056-5 · Cited by 654
Corticotropin-releasing factor, norepinephrine, and stress
Koob, G. F. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00164-x · Cited by 629 · cited 1×
“In turn, norepinephrine enhances forebrain CRF activity, possibly closing a feed-forward loop leading to higher activity of both norepinephrine and CRF in depressed patients (37).”
BackgroundZoccali, C., Mallamaci, F., Parlongo, S., Cutrupi, S., Benedetto, F. A., Tripepi, G., Bonanno, G., Rapisarda, F., Fatuzzo, P., Seminara, G., et al. (2002) · Circulation · doi:10.1161/hc1102.105261 · Cited by 519 · cited 1×
“subjects (20,22), in asymptomatic patients without clinically relevant heart failure (18), in patients with end-stage renal disease without heart failure (19), and in patients with tachyarrhythmias without heart failure (17,30).”
BackgroundMeredith, I. T., Broughton, A., Jennings, G. L., & Esler, M. D. (1991) · New England Journal of Medicine · doi:10.1056/nejm199108293250905 · Cited by 420 · cited 2×
“Possible mechanisms include direct toxic effects of norepinephrine on cardiocytes (16, 31), its ability to trigger tachyarrhythmia (17, 30), and its role in the promotion of platelet aggregation and platelet thrombi formation (18).”
BackgroundDepression, mortality, and medical morbidity in patients with coronary heart disease
Carney, R. M., & Freedland, K. E. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00111-2 · Cited by 378 · cited 1×
“Because a high norepinephrine level is an established risk factor for cardiac events and mortality (17–22), our findings suggest that elevated norepinephrine may contribute to the increased risk of cardiac events associated with depressive symptoms (7).”
Background
Cited by
Whooley, M. A. (2008) · JAMA · doi:10.1001/jama.2008.711 · Cited by 887
“Cortisol was analyzed using radioimmunoassay or (due to a change at the laboratory) highperformance liquid chromatography/ tandem mass spectrometry.(19,20) We used high-pressure liquid chromatography with electrochemical detection to assay whole blood serotonin levels.”
Self-citationComorbid depression in medical diseases
Gold, S. M., Köhler-Forsberg, O., Moss-Morris, R., Mehnert, A., Miranda, J. J., Bullinger, M., Steptoe, A., Whooley, M. A., & Otte, C. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0200-2 · Cited by 534
Self-citationGehi, A., Haas, D., Pipkin, S., & Whooley, M. A. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.21.2508 · Cited by 488
Self-citationHaglund, M. E. M., Nestadt, P. S., Cooper, N. S., Southwick, S. M., & Charney, D. S. (2007) · Development and Psychopathology · doi:10.1017/s0954579407000430 · Cited by 314
Hedayati, S. S., Bosworth, H. B., Briley, L. P., Sloane, R. J., Pieper, C. F., Kimmel, P. L., & Szczech, L. A. (2008) · Kidney International · doi:10.1038/ki.2008.311 · Cited by 292
Metadata
- Authors
- Otte, C., Neylan, T. C., Pipkin, S. S., Browner, W. S., & Whooley, M. A.
- Venue
- American Journal of Psychiatry
- Published
- 2005-11-01
- Volume
- 162
- Issue
- 11
- Pages
- 2139-2145
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2110691600
- Cited by
- 111
- References
- 9
- FWCI
- 4.45
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.